Press Releases OPKO Health, Inc.

Equities

OPK

US68375N1037

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-03 pm EDT			5-day change	1st Jan Change
1.3 ^USD	0.00%		+3.17%	-13.91%

Mar. 28	Laboratory Corp of America to Acquire BioReference's Diagnostics Business Select Assets	MT
Mar. 20	Entera Bio Announces Robust Pharmacokinetic Data for First-In-Class Oral Glp-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

OPKO Health : Immediate Report	May. 04	PU
OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024	May. 03	AQ
InvestorBrandMedia: Wall Street Bulls Eye a 290% Upside on Actinium Pharmaceuticals, Inc. (NYSEAMERICAN: ATNM) Amidst Groundbreaking Cancer Therapy Innovations	Apr. 01	AQ
Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome	Mar. 20	AQ
OPKO Health : Immediate Report	Mar. 15	PU
OPKO Health - AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV	Mar. 06	AQ
AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV	Mar. 05	AQ
OPKO Health : Immediate Report	Mar. 02	PU
OPKO Health : Report of Periodic or Interim Report	Mar. 02	PU
OPKO Health: Q4 Earnings Snapshot	Feb. 27	AQ
OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results	Feb. 27	AQ
Thinking about buying stock in Intuitive Machines, OPKO Health, Ardelyx, AXT Inc, or Clearmind Medicine?	Feb. 23	PR
OPKO Health to Report Fourth Quarter 2023 Financial Results on February 27, 2024	Feb. 22	AQ
OPKO Health Announces Closing of Private Offering of $230 Million Convertible Senior Notes Due 2029 including Full Exercise of Initial Purchaser's Option to Purchase Additional Notes	Jan. 10	AQ
OPKO Health Announces Closing of Private Offering of $230 Million Convertible Senior Notes Due 2029 including Full Exercise of Initial Purchaser’s Option to Purchase Additional Notes	Jan. 09	AQ
OPKO Health to Present at the 42nd Annual J.P. Morgan Healthcare Conference	Jan. 08	AQ
OPKO Health Announces Pricing of Private Offering of $200 Million Convertible Senior Notes Due 2029	Jan. 04	AQ
OPKO Health Announces Private Offering of Convertible Senior Notes Due 2029	Jan. 03	AQ
BioReference Health and Prognos Health Collaborate to Advance Precision Medicine and Testing	Nov. 28	PR
BioReference Signs On as the First Laboratory to Use MSK-ACCESS Powered with SOPHiA DDM	Nov. 08	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases OPKO Health, Inc.

Equities

OPK

US68375N1037

Press Releases

Filters